斯托克治療公司(LENZ) (NASDAQ:STOK)報告稱季度每股虧損爲$(0.18)，好於分析師一致預期的$(0.53)，提高了66.04%。相比去年同期每股虧損$(0.60)，這是70%的增長。公司報告季度銷售額爲$22.60百萬，遠高於分析師一致預期的$4.28百萬，增幅爲428.04%。相比去年同期的$2.80百萬，這一銷售額增長了706.85%。

以上內容來自Benzinga Earnings專欄，原文如下：

Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.53) by 66.04 percent. This is a 70 percent increase over losses of $(0.60) per share from the same period last year. The company reported quarterly sales of $22.60 million which beat the analyst consensus estimate of $4.28 million by 428.04 percent. This is a 706.85 percent increase over sales of $2.80 million the same period last year.